Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCR-T (HPV antigens)
- Development stage
- Preclinical
- Lead developer
- Immunotech Biopharm
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TCR-T (HPV antigens) is an autologous, gene-modified T-cell receptor-engineered T-cell (TCR-T) therapy being developed by Yongtai Biology (Immunotech Biopharm). The therapy involves the genetic modification of a patient's own T cells to express a specific T-cell receptor (TCR) designed to recognize Human Papillomavirus (HPV) derived antigens, such as E6 or E7 proteins, which are presented by Human Leukocyte Antigen (HLA) molecules on the surface of infected or malignant cells. By bypassing the limitations of natural T-cell recognition, this TCR-T approach enables the immune system to specifically target and eliminate HPV-positive tumor cells. The product is currently in preclinical development for the treatment of HPV-associated malignancies, including cervical cancer and head and neck squamous cell carcinomas.
- Other names
- T-cell receptor-engineered T cells (HPV)HPV-specific TCR-T cell therapyHPV antigens-TCR-T cell therapy
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on TCR-T (HPV antigens).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCR-T (HPV antigens).